6505--Ticagrelor Tablets
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NAC PHARMACEUTICALS (36E797)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36E79726R0028
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents3
The Department of Veterans Affairs (VA), through its National Acquisition Center (NAC) Pharmaceuticals division, has issued a solicitation (Procurement Identifier: 36E79726R0028) for the supply of Ticagrelor Tablets. This procurement seeks to secure a reliable source of pharmaceutical-grade Ticagrelor, a medication commonly used to reduce the risk of cardiovascular events, for distribution within the VA healthcare system. The overarching goal is to ensure that veterans have consistent access to high-quality, effective antiplatelet therapy as part of their ongoing medical care.
The scope of this solicitation encompasses the manufacturing and delivery of Ticagrelor Tablets in accordance with all applicable federal regulations and pharmaceutical industry standards. Prospective contractors are expected to demonstrate their capability to produce and supply these tablets at the required quality and volume, adhering to the specifications detailed in the solicitation documents. The anticipated deliverables include the timely provision of Ticagrelor Tablets, with all associated labeling, packaging, and documentation necessary for use within VA medical facilities.
This opportunity is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing), reflecting the requirement for specialized expertise in pharmaceutical production. The Product Service Code (PSC) is 6505, further specifying the focus on drugs and biologicals. The procurement is managed by the NAC Pharmaceuticals office, a federal entity within the Department of Veterans Affairs, ensuring that all contractual and regulatory requirements are strictly observed throughout the contract lifecycle.
Interested parties should note that the solicitation is currently active, with a posting date of September 9, 2026, and a response deadline of September 17, 2026. All inquiries and submissions should be directed to the primary point of contact, Kenneth Lay, via email at [email protected]. Additional details, including solicitation attachments, can be accessed through the official SAM.gov opportunity listing at https://sam.gov/opp/d5658fe117a145ae92d6b84e1b53d850/view.
Contractors considering this opportunity should carefully review the solicitation and its attachments to ensure alignment with their manufacturing capabilities, regulatory compliance history, and capacity to meet the VA’s stringent quality and delivery requirements. This procurement represents a significant opportunity for qualified pharmaceutical manufacturers to support the health and well-being of the nation’s veterans through the reliable supply of a critical medication.